Vera Therapeutics stock snapshot after recent performance

Vera Therapeutics (VERA) has drawn fresh attention after recent price moves, with the stock closing at $32.29 and showing mixed returns, including a decline of about 11% over the past month.

Recent weakness in the share price, including a decline of about 11% over the past month and a year to date share price return down 33.6%, contrasts with a 1 year total shareholder return of 42.3% and a very large 3 year total shareholder return above 7x. This suggests long term holders have still seen strong gains even as shorter term momentum has faded.

If you are curious about other growth oriented healthcare stories that the market is reassessing, it could be a good time to scan 39 healthcare AI stocks

So with Vera Therapeutics pulling back in recent months but still showing very strong multi year returns, is the stock now trading below its true potential, or is the market already pricing in all the future growth?

Preferred Price-to-Book of 4.6x: Is it justified?

On a price-to-book basis, Vera Therapeutics looks expensive right now, with its P/B of 4.6x sitting well above both the US biotech industry and peer averages.

The P/B ratio compares the market value of the stock to the accounting value of its net assets, which can be a useful anchor for companies that are still loss making. In Vera Therapeutics' case, the stock trades at 4.6x book value, while the broader US biotech industry averages 2.3x and its closer peers average 3.7x, so investors are currently paying a clear premium relative to those benchmarks.

This premium suggests the market is assigning extra value to Vera Therapeutics' pipeline and future potential beyond its current balance sheet, despite the company being unprofitable and reporting a loss of $368.953m with less than $1m in revenue. Compared with the industry and peer group, the valuation appears demanding rather than conservative, given the higher P/B starting point.

Result: Price-to-book of 4.6x (OVERVALUED)

However, the company is still loss making, with revenue near zero, and any setback across its clinical programs could quickly challenge the premium P/B multiple.

Another view: DCF points the other way

While the P/B of 4.6x makes Vera Therapeutics look expensive compared with the US biotech industry and peers, the SWS DCF model presents a different perspective. With the stock at $32.29 and the DCF estimate at $446.29, it appears heavily undervalued based on those future cash flow assumptions.

For investors, that gap highlights a clear tension: book value signals caution, while cash flow modelling suggests potential upside. The key question is which signal should carry more weight in your process.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Vera Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Conflicted about the mixed signals in this stock story today? Act while the details are fresh in your mind and weigh up its 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Vera Therapeutics has sharpened your thinking, do not stop here. Use these focused stock ideas to pressure test your portfolio before the next big move.

• Target resilient compounding potential by scanning 61 resilient stocks with low risk scores that aim to keep volatility in check while you stay invested.
• Hunt for quality at a marked down price with screener containing 21 high quality undiscovered gems that the broader market may not be watching yet.
• Strengthen your core holdings by reviewing solid balance sheet and fundamentals stocks screener (46 results) so you are not caught out by weak finances when conditions change.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.